Insulin, corticosteroids and endocrine drugs
Insulin and its preparations, the oral and injectable glucose-lowering drugs and their emergency complications, glucagon, the corticosteroids and their relative potencies, and the drugs used for thyroid disease and for disorders of ADH, at the level of mechanism and principle.
By the end of this page you should be able to
- Describe the actions of insulin, how insulin preparations differ, and the pharmacological basis of its emergency uses.
- Describe the mechanisms and characteristic adverse effects of sulfonylureas, metformin, SGLT2 inhibitors and GLP-1 agonists.
- Explain how glucagon raises glucose and why it can fail.
- Compare the corticosteroids by glucocorticoid and mineralocorticoid activity and duration, and explain their adverse effects and adrenal suppression.
- Describe the mechanisms of the thionamides and other drugs used in thyroid disease, and of desmopressin and vasopressin.
Insulin
Insulin binds a receptor tyrosine kinase; the signal runs through insulin receptor substrates and PI3K. In muscle and fat it moves GLUT4 transporters to the membrane, so glucose enters cells; in the liver it promotes glycogen synthesis and suppresses gluconeogenesis and glycogenolysis; in fat it suppresses lipolysis, and so ketogenesis; it promotes protein synthesis; and it stimulates the Na/K ATPase, moving potassium into cells.
Preparations differ only in absorption from the subcutaneous depot, not in action. Soluble (regular) insulin forms hexamers that must dissociate before absorption; rapid-acting analogues (lispro, aspart, glulisine) are altered to dissociate faster; intermediate isophane insulin is a protamine suspension that releases slowly; long-acting analogues (glargine, which precipitates at tissue pH, and degludec, which forms multihexamer chains) give a flat basal profile. Given IV, soluble insulin has a half-life of only a few minutes, so infusions are titrated quickly and stopping one without basal cover lets ketosis return within hours.
Emergency uses follow from the actions: diabetic ketoacidosis (insulin switches off ketogenesis; glucose is added once it falls so insulin can continue until ketones clear; potassium falls as insulin drives it into cells, so it is checked and replaced first), hyperkalaemia (shift into cells, with glucose to prevent hypoglycaemia), and high-dose insulin euglycaemic therapy for calcium channel blocker and beta blocker poisoning (the poisoned, stressed myocardium depends on glucose, and these drugs impair insulin release and action; insulin restores carbohydrate use and contractility).
Other glucose-lowering drugs
- Sulfonylureas (gliclazide, glipizide, glibenclamide) close ATP-sensitive potassium channels on beta cells, depolarising them and releasing insulin whatever the glucose. Hypoglycaemia can be prolonged and recurrent, especially in older people and renal impairment; giving glucose stimulates further insulin release, which is why octreotide (a somatostatin analogue that inhibits insulin secretion) is used.
- Metformin (a biguanide) reduces hepatic gluconeogenesis, partly by inhibiting mitochondrial complex I and activating AMP kinase, and improves insulin sensitivity. Alone it does not cause hypoglycaemia. Because it impairs lactate use by the liver, accumulation (renal failure, overdose, shock) causes lactic acidosis; metformin is dialysable.
- SGLT2 inhibitors (empagliflozin, dapagliflozin) block proximal glucose reabsorption, causing glycosuria, natriuresis and benefits in heart failure and kidney disease. They can cause euglycaemic ketoacidosis: a lower glucose lowers insulin and raises glucagon, so ketones build while glucose looks reassuring. Risk rises with fasting, surgery and acute illness.
- GLP-1 receptor agonists (semaglutide, dulaglutide) increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying; a full stomach after fasting is a consideration before sedation.
- DPP-4 inhibitors (the gliptins) prolong endogenous GLP-1; low hypoglycaemia risk.
- Glucagon acts on a Gs-coupled liver receptor to drive glycogenolysis and gluconeogenesis. It fails when glycogen is depleted (starvation, alcohol, prolonged hypoglycaemia) and does not counter sulfonylurea-driven insulin release well. It also raises cardiac cAMP independent of beta receptors, the basis for its use in beta blocker poisoning.
Corticosteroids
Glucocorticoids are lipophilic and bind the cytoplasmic glucocorticoid receptor, which moves to the nucleus. Transrepression switches off inflammatory genes (cytokines, COX-2, adhesion molecules, through inhibition of NF-kappaB and AP-1); transactivation switches on others (lipocortin, enzymes of gluconeogenesis), which accounts for many metabolic adverse effects. Most effects take hours, because they need new protein.
- Relative glucocorticoid potency (hydrocortisone = 1): prednisolone about 4, methylprednisolone about 5, dexamethasone about 25 to 30. Mineralocorticoid activity is highest for fludrocortisone, moderate for hydrocortisone, less for prednisolone and negligible for dexamethasone. Duration rises in the same order: hydrocortisone short, prednisolone intermediate, dexamethasone long.
- So hydrocortisone is the drug for adrenal crisis (replaces both actions); dexamethasone suits cerebral oedema around tumours, croup and bacterial meningitis (given with or before the first antibiotic dose) because it has no salt-retaining effect and acts for long; prednisolone is the oral workhorse.
- Adverse effects follow the actions: hyperglycaemia, immunosuppression and masked infection, proximal myopathy, osteoporosis and avascular necrosis, peptic ulceration (especially with NSAIDs), skin thinning, cataract and glaucoma, mood change and psychosis, hypokalaemia and fluid retention with mineralocorticoid activity, and growth suppression in children.
- Adrenal suppression: prolonged supraphysiological doses suppress CRH and ACTH and the adrenal atrophies. Stopping suddenly, or failing to increase the dose during illness or surgery, precipitates adrenal crisis: hypotension, hyponatraemia, hyperkalaemia (when mineralocorticoid is lacking, as in primary failure), hypoglycaemia and collapse.
Thyroid and posterior pituitary drugs
- Thionamides (carbimazole, which is converted to methimazole, and propylthiouracil) inhibit thyroid peroxidase, blocking iodination and coupling. Their effect on circulating hormone is delayed because stored hormone must be used up. Propylthiouracil also blocks peripheral conversion of T4 to T3 and is preferred in early pregnancy; it carries a greater risk of liver injury. Both can cause agranulocytosis: a sore throat or fever on these drugs needs an urgent blood count.
- Iodine in large amounts briefly inhibits hormone release (the Wolff-Chaikoff effect); in thyroid storm it is given only after a thionamide, so the gland cannot use it to make more hormone.
- Beta blockers (propranolol) control adrenergic symptoms in thyrotoxicosis and, at higher levels, reduce T4 to T3 conversion. Corticosteroids also reduce conversion.
- Levothyroxine has a half-life of about a week, so dose changes take weeks to settle. Amiodarone contains a large amount of iodine and can cause both hypo and hyperthyroidism.
- Desmopressin is a selective V2 agonist: treats central diabetes insipidus and releases von Willebrand factor and factor VIII from endothelium (mild haemophilia A, von Willebrand disease, uraemic bleeding). Its key hazard is hyponatraemia from water retention.
- Vasopressin acts on V1 receptors (vasoconstriction, independent of adrenergic receptors) as well as V2; used as a vasopressor in vasodilatory shock.
Making the answer flow
- For insulin, describe the receptor and the effects tissue by tissue, then derive each emergency use from those effects.
- For steroids, give the receptor and gene effects, then a potency and duration table, then adverse effects grouped by system.
- For a glucose-lowering drug, say whether it causes hypoglycaemia on its own and why; that one question sorts most of them.
Where marks are lost
- Saying insulin analogues work differently at the receptor; they differ in absorption.
- Stopping an insulin infusion in DKA when the glucose normalises; ketosis is what is being treated.
- Forgetting that SGLT2 inhibitors cause ketoacidosis with a normal or modest glucose.
- Using dexamethasone to replace mineralocorticoid in adrenal crisis.
- Expecting glucagon to work in a starved or alcoholic patient.
Where this meets anaesthesia
- Dexamethasone given at induction reduces postoperative nausea and may raise blood glucose, particularly in diabetic patients.
- SGLT2 inhibitors can cause euglycaemic ketoacidosis in the perioperative period; they are usually withheld before surgery.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe the actions of insulin.
Show answer
- Tyrosine kinase receptor, IRS, PI3K and Akt signalling.
- Muscle and fat: GLUT4 translocation, glucose uptake; muscle glycogen and protein synthesis.
- Liver: glycogen synthesis, suppression of gluconeogenesis and glycogenolysis.
- Fat: lipogenesis, suppression of lipolysis and so of ketogenesis.
- Potassium, phosphate and magnesium shift into cells via Na/K ATPase.
- 2.
Why does potassium need attention before and during insulin treatment of DKA?
Show answer
- Total body potassium is depleted by osmotic diuresis and vomiting, though plasma potassium may be normal or high from acidosis and insulin lack.
- Insulin drives potassium into cells; plasma levels can fall quickly, causing arrhythmias and weakness.
- Low potassium is corrected before insulin starts; potassium is added to fluids and monitored often.
- 3.
Why does a sulfonylurea overdose cause recurrent hypoglycaemia, and how is octreotide useful?
Show answer
- Sulfonylureas close K-ATP channels, causing glucose-independent insulin release; long-acting drugs and active metabolites accumulate in renal impairment.
- Dextrose raises glucose, which further stimulates the sensitised beta cells: rebound hypoglycaemia.
- Octreotide binds somatostatin receptors on beta cells, reducing calcium entry and insulin release, breaking the cycle.
- 4.
How does metformin cause lactic acidosis?
Show answer
- Inhibits mitochondrial complex I and hepatic gluconeogenesis, so the liver takes up and converts less lactate.
- Shifts metabolism towards anaerobic glycolysis.
- Accumulates in renal failure or overdose; risk compounded by shock, sepsis and liver disease.
- Small, water-soluble, low protein binding: removable by haemodialysis.
- 5.
Explain euglycaemic ketoacidosis with SGLT2 inhibitors.
Show answer
- Glycosuria lowers plasma glucose, so insulin secretion falls and glucagon rises.
- Low insulin to glucagon ratio drives lipolysis and ketogenesis.
- Glucose may be near normal, so the ketoacidosis is missed unless ketones and acid-base are measured.
- Triggers: fasting, surgery, acute illness, insulin dose reduction, alcohol.
- 6.
Compare hydrocortisone, prednisolone and dexamethasone.
Show answer
- Glucocorticoid potency relative to hydrocortisone: prednisolone about 4, dexamethasone about 25 to 30.
- Mineralocorticoid activity: hydrocortisone significant, prednisolone less, dexamethasone negligible.
- Duration: short, intermediate, long.
- Uses: hydrocortisone for adrenal crisis; prednisolone for most oral anti-inflammatory use; dexamethasone for cerebral oedema, croup, meningitis, antiemesis.
- 7.
What is adrenal suppression and how does it present?
Show answer
- Exogenous glucocorticoid suppresses hypothalamic CRH and pituitary ACTH; the adrenal cortex atrophies.
- Abrupt withdrawal or failure to increase cover in stress unmasks deficiency.
- Adrenal crisis: hypotension resistant to fluids and vasopressors, vomiting, abdominal pain, hyponatraemia, hypoglycaemia, confusion.
- Treated with parenteral hydrocortisone and fluids; doses per local guidelines.
- 8.
How do the drugs used in thyroid storm work?
Show answer
- Thionamide: blocks synthesis (thyroid peroxidase); propylthiouracil also blocks peripheral T4 to T3 conversion.
- Iodine after the thionamide: blocks release of stored hormone.
- Beta blocker: controls adrenergic effects; propranolol reduces conversion.
- Corticosteroid: reduces conversion and treats relative adrenal insufficiency; plus cooling and treating the trigger.
- 9.
How does desmopressin help a bleeding patient?
Show answer
- V2 agonist on endothelial cells causes release of stored von Willebrand factor and factor VIII.
- Useful in mild haemophilia A, type 1 von Willebrand disease, uraemic platelet dysfunction and some antiplatelet bleeding.
- Tachyphylaxis with repeated doses as stores deplete; hyponatraemia from V2 effect on the collecting duct.
Practise this week
- Primary MCQs: pharmacology
- Primary SAQs, marked part by part
- Primary vivas
- Viva Examiner: practise answering aloud
Week 19 in the other subjects
- Physiology: Gut, liver and nutrition
- Procedural anatomy: Hip, thigh and femoral triangle
Not affiliated with the Australian and New Zealand College of Anaesthetists (ANZCA). Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.